BG Medicine, which develops and commercializes molecular diagnostics based on biomarkers, filed on Friday with the SEC to raise up to $86 million in an initial public offering. The Waltham, MA-based company, which was founded in 2000 and booked $8 million in sales over the last 12 months, plans to list on the NASDAQ under the symbol BGMD. It previously filed to go public in August of 2007 but withdrew the deal in January of 2008 due to market conditions. Jefferies and UBS Investment Bank are the lead underwriters on the deal, for which pricing terms and timing were not disclosed. Of the four companies that have filed so far this week, three are venture backed; BG Medicine is 44% owned by Flagship Ventures.
